Gilead Sciences | GILD - Текущие активы





Текущие активы Изменить Дата
AbbVie USD 37.48B 3.81B 2026-09
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
ALKERMES USD 1.58B 57.83M 2026-09
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amgen USD 34.36B 598M 2026-09
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Coherus Biosciences USD 133.79M 72.25M 2026-06
Eli Lilly USD 65.26B 591M 2026-09
Gilead Sciences USD 16.55B 4.02B 2026-09
GlaxoSmithKline GBP 17.9B 336M 2026-09
Glaxosmithkline GBP 17.9B 134M 2026-09
Incyte USD 5.52B 505.2M 2026-09
J&J USD 56.35B 3.42B 2026-09
Merck USD 38.94B 2.26B 2026-09
Moderna USD 5.82B 45M 2026-06
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Novartis USD 28.75B 1.4B 2026-09
Pfizer USD 45.01B 3.65B 2026-09
PTC Therapeutics USD 2.54B 79.58M 2026-09
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 33.21B 1.68B 2026-09
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
United Therapeutics USD 2.88B 603.5M 2026-09
Vertex Pharmaceuticals USD 11.69B 857.4M 2026-09